
Realm Therapeutics shares halved after failure of Phase 2 study
pharmafile | August 15, 2018 | News story | Research and Development |Â Â London, Shares, atopic dermatitis, phase 2, stock marketÂ
Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the experimental drug PR022 had failed to meet its primary endpoint in people with atopic dermatitis.
Shares in the company dropped in price by more than half after a randomized, double-blind, vehicle controlled clinical trial of 122 patients showed that PR022 showed no difference from vehicle.
“PR022 did not show the desired effect in this trial,” said Alex Martin, CEO of Realm Therapeutics. “Having just received the data, we are working to better understand this outcome and to analyse all of the data collected in the study. We are conducting a full review to determine whether there is a path forward for our proprietary technology in Atopic Dermatitis, and to evaluate the implications for our Acne and Psoriasis programs. We will provide an update on our plans in September. I would like to thank the patients and investigators who participated in this trial.”
Share prices dropped from 39.00 GBX on Monday to 17.26 GBX the following day. They now lie at a low of 15.05 GBX as they continue to fall.
The company is now investigating PR022 for use in treating psoriasis. However the news comes as it was announced in March that the topical ophthalmic solution PR013 had failed to meet primary endpoints in a Phase II trial for the treatment of allergic conjunctivitis.
Louis Goss
Related Content

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

Dupixent improves symptoms in patients with skin of colour, study shows
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …

Ambitious plans for leading cancer research centre announced
Aviva Capital Partners (ACP), an infrastructure and real estate investor, and Socius, a mixed-use developer, …






